Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Omvoh Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy CS2026D00129K

    Omvoh (mirikizumab-mrkz) Coverage Criteria

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS2026D00129K alerts

    Get alerted when Policy CS2026D00129K changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit prior authorization and medical-necessity coverage for Omvoh in adults with moderately to severely active ulcerative colitis or Crohn's disease; self-administered subcutaneous Omvoh is covered under the pharmacy benefit.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOmvoh (mirikizumab-mrkz) Coverage Criteria
    Policy CodePolicy CS2026D00129K
    Change TypeClarification
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of diagnosis, disease activity, prior targeted-therapy trials, and the three-dose intravenous induction regimen for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history states that language was added clarifying that this Medical Benefit Drug Policy does not apply to Florida.

    3IV induction doses
    65%UC response after induction
    24%UC remission after induction
    506UC maintenance study subjects

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Excluded
    Florida applicability

    Coverage Criteria

    Ulcerative Colitis (UC) — Initial Therapy

    Omvoh is proven and medically necessary for the treatment of moderately to severely active ulcerative colitis when <strong>all</strong> of the following criteria are met:

    ALL of the following

    • Diagnosis of moderately to severely active ulcerative colitis.
    • ONE of the following

      • Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, such as azathioprine or 6-mercaptopurine.
      • Previously treated with a systemic targeted immunomodulator FDA-approved for the treatment of ulcerative colitis, such as adalimumab, Entyvio (vedolizumab), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), ustekinumab, or Zeposia (ozanimod).
    • History of failure, contraindication, or intolerance to two targeted immunomodulators FDA-approved for the treatment of ulcerative colitis; document the drug, date, and duration of each trial.
    • Omvoh is to be administered as three intravenous induction doses.
    • Omvoh induction dosing is in accordance with the FDA-labeled dosing for ulcerative colitis.
    • Patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication.
    • Omvoh is prescribed by or in consultation with a gastroenterologist.
    • Authorization will be issued for 3 induction doses.

    Crohn's Disease (CD) — Initial Therapy

    Omvoh is medically necessary for the treatment of moderately to severely active Crohn's disease when <strong>all</strong> of the following criteria are met:

    ALL of the following

    • Diagnosis of moderately to severely active Crohn's disease.
    • ONE of the following

      • History of failure to one of the following conventional therapies at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced: corticosteroids such as prednisone, methylprednisolone, or budesonide; 6-mercaptopurine (Purinethol); azathioprine (Imuran); or methotrexate (Rheumatrex, Trexall).
      • Previously treated with a systemic targeted immunomodulator FDA-approved for the treatment of Crohn's disease, such as adalimumab, Cimzia (certolizumab), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi (risankizumab), Tremfya (guselkumab), or ustekinumab.

    Omvoh must not be used in combination with another systemic targeted immunomodulator for treatment of the same indication.

    This Medical Benefit Drug Policy does not apply in Arizona, Florida, Indiana, Kansas, North Carolina, Ohio, Pennsylvania, Texas, or Washington. Refer to the applicable state-specific policy or guideline: Arizona, Indiana, Pennsylvania, and Washington—state Medicaid clinical policy; North Carolina—no state policy or guideline noted; Ohio—Immunomodulatory Agents for Systemic Inflammatory Diseases (for Ohio Only); Texas—drug-specific criteria in the Texas Medicaid Provider Procedures Manual; Florida—state Medicaid clinical policy.

    This Medical Benefit Drug Policy does not apply to Florida. Refer to the state's Medicaid clinical policy.

    Coding and Clinical Parameters

    Applicable HCPCS CodeHCPCS
    J2267Injection, mirikizumab-mrkz, 1 mg
    Crohn's Disease Diagnosis CodesICD-10
    K50.00Crohn's disease of small intestine without complications
    K50.011Crohn's disease of small intestine with rectal bleeding
    K50.012Crohn's disease of small intestine with intestinal obstruction
    K50.013Crohn's disease of small intestine with fistula
    K50.014Crohn's disease of small intestine with abscess
    K50.018Crohn's disease of small intestine with other complication
    K50.019Crohn's disease of small intestine with unspecified complications
    K50.10Crohn's disease of large intestine without complications
    K50.111Crohn's disease of large intestine with rectal bleeding
    K50.112Crohn's disease of large intestine with intestinal obstruction
    1–10 of 25
    1/3
    Ulcerative Colitis Diagnosis CodesICD-10
    K51.00
    K51.012
    K51.013Ulcerative (chronic) pancolitis with fistula
    K51.014
    K51.018Ulcerative (chronic) pancolitis with other complication
    K51.019
    K51.20Ulcerative (chronic) proctitis without complications
    K51.211Ulcerative (chronic) proctitis with rectal bleeding
    K51.212Ulcerative (chronic) proctitis with intestinal obstruction
    K51.213Ulcerative (chronic) proctitis with fistula
    1–10 of 49
    1/5
    Intravenous induction doses
    Induction regimenThree intravenous induction doses
    Authorization quantityAuthorization is issued for 3 induction doses
    Dosing requirementInduction dosing must follow FDA-labeled dosing for the applicable indication
    Moderately to severely active disease
    Modified Mayo score5 to 9
    Endoscopy requirementCentrally read endoscopy subscore of 2 or 3

    Provider Actions and Coverage Decisions

    Prior Authorization

    Medical-Benefit Prior Authorization Required

    Prior authorization is required for medical-benefit Omvoh. Initial authorization is limited to three intravenous induction doses; self-administered subcutaneous Omvoh is obtained under the pharmacy benefit.

    • Submit documentation supporting the applicable diagnosis, disease activity, prior-treatment requirements, dosing, and prescriber qualifications.
    • Authorization will be issued for 3 induction doses.
    Step Therapy

    Ulcerative Colitis Step Therapy

    For ulcerative colitis, document inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressive therapy, or the applicable prior targeted-immunomodulator treatment history.

    • Oral corticosteroid examples include prednisone, methylprednisolone, or budesonide.
    • Immunosuppressive examples include azathioprine and 6-mercaptopurine.

    Drug Background

    Omvoh (mirikizumab-mrkz) is a humanized IgG4 monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and inhibits its interaction with the interleukin-23 receptor. It is an interleukin-23 antagonist evaluated for treatment of moderately to severely active ulcerative colitis and Crohn's disease.

    Definitions

    Modified Mayo score
    Score range0 to 9
    ComponentsStool frequency, rectal bleeding, and findings on centrally read endoscopy
    Component scoringEach subscore ranges from 0 (normal) to 3 (most severe)
    Severely active diseaseScores of 7 to 9 indicate severely active disease in the described study
    Endoscopy subscore
    Score scaleThe endoscopy subscore ranges from 0 (normal) to 3 (most severe)
    Score 2Marked erythema, absent vascular pattern, friability, and erosions

    Initial Therapy Authorization

    Ulcerative Colitis Initial Authorization

    Ulcerative colitis initial authorization requires all of the following conditions:

    All required authorization conditions

    • Diagnosis of moderately to severely active ulcerative colitis.
    • ONE of the following prior-treatment alternatives

      • Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, such as azathioprine or 6-mercaptopurine.
      • Previous treatment with a systemic targeted immunomodulator FDA-approved for the treatment of ulcerative colitis.
    • History of failure, contraindication, or intolerance to two targeted immunomodulators FDA-approved for the treatment of ulcerative colitis. Document the drug, date, and duration of each trial.

    Step Therapy Requirements

    StepPrior-treatment alternativeTargeted immunomodulator requirement
    1Inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, or prior treatment with an FDA-approved systemic targeted immunomodulator for ulcerative colitis.Failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for ulcerative colitis; document the drug, date, and duration of each trial.
    StepPrior-treatment alternativeTargeted immunomodulator requirement
    1Failure of one conventional therapy at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred, or prior treatment with an FDA-approved systemic targeted immunomodulator for Crohn's disease.Failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for Crohn's disease; document the drug, date, and duration of each trial.

    Quantity Limits

    Omvoh quantity limit
    DrugOmvoh (mirikizumab-mrkz)
    Quantity limit3 induction doses per course
    RouteIntravenous doses

    Site of Care and Benefit Routing

    Billing Rule

    Administer induction doses in an infusion center

    Medical-benefit Omvoh is administered as three intravenous induction doses in an infusion-center setting. The induction dosing must follow the FDA-labeled dosing for the applicable indication.

    • Initial authorization is for three intravenous induction doses
    Billing Rule

    Route self-administered Omvoh through the pharmacy benefit

    Self-administered subcutaneous Omvoh is obtained under the pharmacy benefit rather than this medical-benefit drug policy.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOmvoh (mirikizumab-mrkz) Coverage Criteria
    Policy CodePolicy CS2026D00129K
    Change TypeClarification
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of diagnosis, disease activity, prior targeted-therapy trials, and the three-dose intravenous induction regimen for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Actions and Coverage DecisionsDrug BackgroundDefinitionsInitial Therapy AuthorizationStep Therapy RequirementsQuantity LimitsSite of Care and Benefit Routing
    History of failure, contraindication, or intolerance to two targeted immunomodulators FDA-approved for the treatment of Crohn's disease; document the drug, date, and duration of each trial.
  1. Omvoh is to be administered as three intravenous induction doses.
  2. Omvoh induction dosing is in accordance with the FDA-labeled dosing for Crohn's disease.
  3. Patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication.
  4. Omvoh is prescribed by or in consultation with a gastroenterologist.
  5. Authorization will be issued for 3 induction doses.
  6. Disease assessment
    The score assesses stool frequency, rectal bleeding, and centrally read endoscopy
    Crohn's Disease Activity Index
    Assessment measureCrohn's Disease Activity Index (CDAI)
    Required thresholdAt least 220
    Study contextUsed to define moderately to severely active Crohn's disease in Study CD-1
    SES-CD threshold for ileal-colonic disease
    Assessment measureSimple Endoscopic Score for Crohn's Disease (SES-CD)
    Disease distributionIleal-colonic disease
    Required thresholdAt least 7, centrally read
    SES-CD threshold for isolated ileal disease
    Assessment measureSimple Endoscopic Score for Crohn's Disease (SES-CD)
    Disease distributionIsolated ileal disease
    Required thresholdAt least 4, centrally read
  7. Document the required history of failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for ulcerative colitis.
  8. Step Therapy

    Crohn's Disease Step Therapy

    For Crohn's disease, document failure of at least one conventional therapy at up to maximally indicated doses, unless the therapy is contraindicated or clinically significant adverse effects are experienced.

    • Qualifying conventional therapies include corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate.
    • Also document the required history of failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for Crohn's disease.

    Unsupported block type: documentation

    Documentation Required

    Diagnosis and Disease Activity Documentation

    The medical record must establish a diagnosis of moderately to severely active ulcerative colitis or Crohn's disease, as applicable, and include documentation supporting the required prior-treatment history.

    • For ulcerative colitis, document moderately to severely active disease and the applicable corticosteroid, immunosuppressive, and/or targeted-immunomodulator treatment history.
    • For Crohn's disease, document moderately to severely active disease and failure of qualifying conventional therapy, together with the required targeted-immunomodulator history.
    Documentation Required

    Prescriber and Induction Regimen

    The prescription and administration plan must identify the prescriber and support the FDA-labeled induction regimen. Omvoh induction consists of three intravenous doses for the applicable indication.

    • Document that the drug is prescribed by or in consultation with a gastroenterologist.
    • Document three intravenous induction doses and administration details.
    • Confirm that induction dosing follows the FDA-labeled dosing for ulcerative colitis or Crohn's disease, as applicable.
    Denial Risk

    Ulcerative Colitis Criteria Not Met

    Coverage for Omvoh for ulcerative colitis may be denied when the diagnosis or disease activity is not documented, or when the required prior-treatment criteria are not satisfied.

    • Denial risk includes no documentation of moderately to severely active ulcerative colitis.
    • Denial risk includes failure to document inadequate response to oral corticosteroids and/or immunosuppressive therapy when that pathway is used.
    • Denial risk includes failure to document failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for ulcerative colitis.
    Denial Risk

    Crohn's Disease Criteria Not Met

    Coverage for Omvoh for Crohn's disease may be denied when the diagnosis or disease activity is not documented, or when the required prior-treatment criteria are not satisfied.

    • Denial risk includes no documentation of moderately to severely active Crohn's disease.
    • Denial risk includes failure to document failure of a qualifying conventional therapy at up to maximally indicated doses, unless contraindicated or clinically inappropriate because of significant adverse effects.
    • Denial risk includes failure to document failure, contraindication, or intolerance to two FDA-approved targeted immunomodulators for Crohn's disease.
    Note

    State-Specific Policy Applies

    This medical-benefit policy does not apply in the listed states. Providers must follow the applicable state-specific Medicaid policy or guideline instead.

    • Excluded states: Arizona, Florida, Indiana, Kansas, North Carolina, Ohio, Pennsylvania, Texas, and Washington.
    • Refer to the applicable state policy identified in the source policy for the relevant state.
    Denial Risk

    FDA Approval Alone Does Not Establish Coverage

    FDA approval alone does not establish coverage for Omvoh. Coverage remains subject to the member's benefit plan and all applicable policy requirements.

    • Omvoh is FDA-indicated for adults with moderately to severely active ulcerative colitis and Crohn's disease.
    • FDA indication does not replace documentation of medical necessity, prior-treatment, dosing, and other coverage criteria.
    Billing Rule

    Benefit Requirements Control

    Before determining coverage, verify the federal, state, and contractual benefit requirements that apply to the member's plan. If those requirements conflict with this policy, the applicable benefit requirements govern.

    • Check federal, state, and contractual requirements before applying the standard policy criteria.
    • Coverage decisions must be made under the controlling benefit-plan terms.
    Score 3Spontaneous bleeding and ulceration
    Omvoh (mirikizumab-mrkz)
    DrugOmvoh (mirikizumab-mrkz)
    Drug classInterleukin-23 antagonist
    FDA-labeled indicationsTreatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults
    Moderately to severely active Crohn's disease
    StudyStudy CD-1
    CDAI thresholdAt least 220
    SES-CD thresholdAt least 7 for ileal-colonic disease or at least 4 for isolated ileal disease, centrally read
  9. Omvoh is administered as three intravenous induction doses.3 intravenous induction doses
  10. Omvoh induction dosing is in accordance with the FDA-labeled dosing for ulcerative colitis.
  11. The patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication.
  12. Omvoh is prescribed by or in consultation with a gastroenterologist.
  13. Authorization is issued for 3 induction doses.3 induction doses
  14. Crohn's Disease Initial Authorization

    Crohn's disease initial authorization requires all of the following conditions:

    All required authorization conditions

    • Diagnosis of moderately to severely active Crohn's disease.
    • ONE of the following prior-treatment alternatives

      • History of failure to one conventional therapy at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced. Conventional therapies include corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate.

        The exception applies when the conventional therapy is contraindicated or clinically significant adverse effects are experienced.

      • Previous treatment with a systemic targeted immunomodulator FDA-approved for the treatment of Crohn's disease.
    • History of failure, contraindication, or intolerance to two targeted immunomodulators FDA-approved for the treatment of Crohn's disease. Document the drug, date, and duration of each trial.
    • Omvoh is administered as three intravenous induction doses.3 intravenous induction doses
    • Omvoh induction dosing is in accordance with the FDA-labeled dosing for Crohn's disease.
    • The patient is not receiving Omvoh in combination with another systemic targeted immunomodulator for treatment of the same indication.
    • Omvoh is prescribed by or in consultation with a gastroenterologist.
    • Authorization is issued for 3 induction doses.3 induction doses